Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
Clinical trial NCT05766748 · UNKNOWN
Trial details
- NCT number
- NCT05766748
- Sponsor
- Cantex Pharmaceuticals
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-01
- Primary completion
- 2025-02-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.